Fampridine - paediatric investigation plan

Fampridine

Key facts

• Active Substance:
  Fampridine
• Therapeutic area:
  Neurology
• Decision number:
  P/213/2010
• PIP number:
  Fampridine
• Pharmaceutical form(s):
  Prolonged-release tablet
• Condition(s) / indication(s):
  Multiple sclerosis with walking disability
• Route(s) of administration:
  Oral use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  30/10/2010

Decision

P/213/2010: European Medicines Agency decision of 29 October 2010 on the granting of a product specific waiver for fampridine (EMEA-000614-PIP01-10-M01)

AdoptedReference Number: EMA/655503/2010